9th Market Access, Pricing & Reimbursement Global Congress 2023 Europe

Agenda at a Glance

Day 2 - Congress

Day 2: Friday 5nd May 2023

Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross

CHALLENGES & OPPORTUNITIES

  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship

Moderator:

Panellist:

  • Andrew Stainthorpe, Head of Market Access, Oxford AHSN
  • Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Future trends and developments in the healthcare distribution

Sjaak Vink, Chief Executive Officer, The SocialMedwork

  • New cell and gene therapies are often characterized by fat tail probability functions (i.e. small probability
    of very large gains)
  • Traditional statistical methods are often not appropriate in this context to determine value.
  • Instead, patient preferences are key. They should be systematically included in regulatory and
    reimbursement decisions.

Jörg Mahlich, Market Access & Government Affairs Lead, Miltenyi Biomedicine

  • Innovative approaches required to address the medicine access challenge
  • Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
  • The value of list prices against the backdrop of external price referencing and managed entry
    agreements.
  • Innovative policy options that need to be developed, agreed upon and implemented.

Moderator:
Andrew Stainthorpe, Head of Market Access, Oxford AHSN

Panellist:
Olga Katzelnik, Market Access Lead Europe/International, Regeneron
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
Jörg Mahlich, Market Access & Government Affairs Lead, Miltenyi Biomedicine

  • Why, when and how could you collaborate for access
  • Overcoming barriers to collaboration
  • What can we learn from Duchenne UK’s project HERCULES?

Josie Godfrey, Co-Founder and CEO, Realise Advocacy

  • Why is this important
  • Current state of play
  • Barriers to Equity Pricing
  • Potential solutions and some principles to maximize impact of Equity Pricing

Ana Plata, Global Pricing Head, AstraZeneca Biopharmaceuticals

  • Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to
    innovative therapies
  • Why is the full stakeholder ecosystem important for gaining access in the future?
  • How to Identify the stakeholder ecosystem for access success
  • Step by step: Setting up a cross-functional program for access success

Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross

  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?

Panellist:
Andrew Stainthorpe, Head of Market Access, Oxford AHSN
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
Josie Godfrey, Co-Founder and CEO, Realise Advocacy

Scroll to Top